Clinical Policy: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

Reference Number: AZ.CP.PMN.43
Effective Date: 09.04.18
Last Review Date: 02.22
Line of Business: Arizona Medicaid (AzCH-CCP and Care1st) Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Description

The following are dipeptidyl peptidase-4 (DPP-4) inhibitors requiring prior authorization: alogliptin (Nesina®), alogliptin/metformin (Kazano®), alogliptin/pioglitazone (Oseni®), linagliptin (Tradjenta®), linagliptin/empagliflozin (Glyxambi®), linagliptin/metformin (Jentadueto®, Jentadueto® XR), saxagliptin (Onglyza®), saxagliptin/metformin (Kombiglyze® XR), sitagliptin (Januvia®), ertugliflozin/sitagliptin (Steglujan®), sitagliptin/metformin (Janumet®, Janumet® XR), dapagliflozin/saxagliptin (Qtern®), and empagliflozin/linagliptin/metformin (Trijardy™ XR).

AHCCCS preferred drugs in this class include Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin extended-release), Jentadueto (linagliptin/metformin), Jentadueto XR (linagliptin/metformin extended-release), Kazano (alogliptin/metformin), Kombiglyze XR (saxagliptin/metformin extended-release), Nesina (alogliptin), Onglyza (saxagliptin), Oseni (alogliptin/pioglitazone), and Tradjenta (linagliptin).

**If request is for a combination DPP-4 inhibitor and sodium glucose co-transporter 2 (SGLT2) inhibitor (e.g., linagliptin/empagliflozin [Glyxambi®], linagliptin/empagliflozin/metformin [Trijardy™ XR], saxagliptin/dapagliflozin [Qtern®], sitagliptin/ertugliflozin [Steglujan™]), refer to AZ.CP.PMN.14 SGLT2 Inhibitors.*

FDA Approved Indication(s)

DPP-4 inhibitors are indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitation(s) of use:

- DPP-4 inhibitors should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
- DPP-4 inhibitors have not been studied in patients with a history of pancreatitis.

Policy/Criteria

Provider must submit documentation (including such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of Arizona Complete Health-Complete Care Plan and Care1st that DPP-4 inhibitors are **medically necessary** when the following criteria are met:

CLINICAL POLICY
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

I. Initial Approval Criteria

A. Type 2 Diabetes Mellitus (must meet all)**:**

1. Diagnosis of type 2 diabetes mellitus;
2. Age ≥ 18 years;
3. Member meets one of the following (a or b):
   a. Failure of ≥ 3 consecutive months of metformin at a minimum daily dose of 1500mg, unless contraindicated or clinically significant adverse effects are experienced;
   b. HbA1c drawn within the past 3 months is ≥ 8.5%, and concurrent use of metformin at a minimum daily dose of 1500mg, unless contraindicated or clinically significant adverse effects are experienced;
4. Dose does not exceed the FDA approved maximum recommended dose (*see Section V*).

Approval duration: 12 months

B. Other diagnoses/indications

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): AZ.CP.PMN.53 for Arizona Medicaid.

II. Continued Therapy

A. Type 2 Diabetes Mellitus (must meet all)**:**

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. Documentation of continued metformin therapy (unless contraindicated);
4. If request is for a dose increase, the new dose does not exceed the FDA approved maximum recommended dose (*see Section V*).

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2)**:**

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
   Approval duration: Duration of request or 12 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): AZ.CP.PMN.53 for Arizona Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – AZ.CP.PMN.53 for Arizona Medicaid.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

AACE: American Association of Clinical Endocrinologists
ACE: American College of Endocrinology
ADA: American Diabetes Association
DPP-4: dipeptidyl peptidase-4
FDA: Food and Drug Administration
GLP-1: glucagon-like peptide-1
HbA1c: glycated hemoglobin
SGLT2: sodium-glucose co-transporter 2

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
metformin (Fortamet®, Glucophage®, Glucophage® XR, Glumetza®)	Regular-release (Glucophage): 500 mg PO BID or 850 mg PO QD; increase as needed in increments of 500 mg/week or 850 mg every 2 weeks Extended-release: • Fortamet, Glumetza: 1,000 mg PO QD; increase as needed in increments of 500 mg/week • Glucophage XR: 500 mg PO QD; increase as needed in increments of 500 mg/week	Regular-release: 2550 mg/day Extended-release: • Fortamet: 2500 mg/day • Glucophage XR: 2000 mg/day
Glyxambi (empagliflozin/linagliptin)	Initial, empagliflozin 10 mg/linagliptin 5 mg PO QD, may increase to empagliflozin 25 mg/linagliptin 5 mg PO QD	Empagliflozin 25 mg/linagliptin 5 mg
Januvia (sitagliptin)	100 mg PO once daily	100 mg/day
Janumet (sitagliptin/metformin)	Initial, sitagliptin 50 mg/metformin 500 mg PO BID, may increase to sitagliptin 50 mg/metformin 1000 mg PO BID	Sitagliptin 100 mg/metformin 2000 mg
Janumet XR (sitagliptin/metformin extended-release)	Sitagliptin 100 mg/metformin 1000 mg PO QD	Sitagliptin 100 mg/metformin 2000 mg

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Jentadueto (linagliptin/metformin)	Linagliptin 2.5 mg/metformin 500 mg PO BID with a meal	Linagliptin 5 mg/ metformin 2,000 mg
Jentadueto XR (linagliptin/metformin)	Linagliptin 5 mg/metformin 1000 mg PO QD with meals	Linagliptin 5 mg/ metformin 2,000 mg
Kazano (alogliptin/metformin)	Alogliptin 12.5 mg/metformin 500 mg PO BID with meals	Alogliptin 25 mg/metformin 2000 mg
Kombiglyze XR (saxagliptin/metformin extended-release)	Metformin 500 mg/saxagliptin 5 mg PO QD	Metformin 2,000 mg/saxagliptin 5 mg
Nesina (alogliptin)	Initial, 25 mg PO QD	25 mg/day
Onglyza (saxagliptin)	Initial, 2.5 to 5 mg PO QD	5 mg/day
Oseni (alogliptin/pioglitazone)	Alogliptin 25 mg/pioglitazone 15 mg PO QD	Alogliptin 25 mg/pioglitazone 45 mg
Tradjenta (linagliptin)	Initial, 5 mg PO QD	5 mg/day
Trijardy XR (empagliflozin/linagliptin/ metformin)	Individualized dose PO QD	25/5/2,000 mg/day

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
  - History of serious hypersensitivity reaction to the requested drug product
  - Severe renal impairment (*metformin-containing products*)
  - Metabolic acidosis, including diabetic ketoacidosis (*metformin-containing products only*)
  - NYHA Class III or IV heart failure (*Oseni only*)
- Boxed warning(s): lactic acidosis (*metformin-containing products only*), congestive heart failure (*Oseni only*)

Appendix D: General Information

- A double-blind, placebo-controlled dose-response trial by Garber et al. found the maximal efficacy of metformin to occur at doses of 2,000 mg. However, the difference in adjusted mean change in HbA1c between the 1,500 and 2,000 mg doses was 0.3%,

suggesting that the improvement in glycemic control provided by the additional 500 mg may be insufficient when HbA1c is > 7%.

- Per the 2020 American Diabetes Association (ADA) and 2020 American Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE) guidelines:
  - Metformin is recommended for all patients with type 2 diabetes. Monotherapy is recommended for most patients; however:
    - Starting with dual therapy (i.e., metformin plus another agent, such as a sulfonylurea, thiazolidinedione, dipeptidyl peptidase-4 inhibitor, sodium-glucose co-transporter inhibitor, GLP-1 receptor agonist, or basal insulin) may be considered for patients with baseline HbA1c ≥ 1.5% above their target per the ADA (≥ 7.5% per the AACE/ACE). According to the ADA, a reasonable HbA1c target for many non-pregnant adults is < 7% (≤ 6.5% per the AACE/ACE).
    - Starting with combination therapy with insulin may be considered for patients with baseline HbA1c > 10% per the ADA (> 9% if symptoms are present per the AACE/ACE).
  - If the target HbA1c is not achieved after approximately 3 months of monotherapy, dual therapy should be initiated. If dual therapy is inadequate after 3 months, triple therapy should be initiated. Finally, if triple therapy fails to bring a patient to goal, combination injectable therapy should be initiated. Each non-insulin agent added to initial therapy can lower HbA1c by 0.7-1%.

V. Dosage and Administration

Drug Name	Dosing Regimen	Maximum Dose
Janumet (sitagliptin/metformin)	Individualized dose PO BID	100/2000 mg/day
Janumet XR (sitagliptin/metformin)	Individualized dose PO QD	100/2000 mg/day
Januvia (sitagliptin)	100 mg PO QD	100 mg/day
Jentadueto (linagliptin/metformin)	Individualized dose PO BID	5/2000 mg/day
Jentadueto XR (linagliptin/metformin)	Individualized dose PO QD	5/2000 mg/day
Kazano (alogliptin/metformin)	Individualized dose PO BID	25/2000 mg/day
Kombiglyze XR (saxagliptin/metformin)	Individualized dose PO QD	5/2000 mg/day
Nesina (alogliptin)	25 mg PO QD	25 mg/day
Onglyza (saxagliptin)	2.5 or 5 mg PO QD	5 mg/day
Oseni (alogliptin/pioglitazone)	Individualized dose PO QD	25/45 mg/day
Tradjenta (linagliptin)	5 mg PO QD	5 mg/day

VI. Product Availability

Drug Name	Availability
Janumet (sitagliptin/metformin)	Tablets: 50/500 mg, 50/1000 mg

Drug Name	Availability
Janumet XR (sitagliptin/metformin)	Tablets: 100/1000 mg, 50/500 mg, 50/1000 mg
Januvia (sitagliptin)	Tablets: 25 mg, 50 mg, 100 mg
Jentadueto (linagliptin/metformin)	Tablets: 2.5/500 mg, 2.5/850 mg, 2.5/1000 mg
Jentadueto XR (linagliptin/metformin)	Tablets: 5/1000 mg, 2.5/1000 mg
Kazano (alogliptin/metformin)	Tablets: 12.5/500 mg, 12.5/1000 mg
Kombiglyze XR (saxagliptin/metformin)	Tablets: 5/500 mg, 5/1000 mg, 2.5/1000 mg
Nesina (alogliptin)	Tablets: 6.25 mg, 12.5 mg, 25 mg
Onglyza (saxagliptin)	Tablets: 2.5 mg, 5 mg
Oseni (alogliptin/pioglitazone)	Tablets: 12.5/15 mg, 12.5/30 mg, 12.5/45 mg, 25/15 mg, 25/30 mg, 25/45 mg
Tradjenta (linagliptin)	Tablets: 5 mg

VII. References

1. American Diabetes Association. Standards of medical care in diabetes—2020. Diabetes Care. 2020;43 (suppl 1): S1-S212. Updated June 16, 2021. Accessed September 16, 2021.
2. Glyxambi Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; June 2021. Available at: www.glyxambi.com. Accessed September 16, 2021.
3. Janumet Prescribing Information. Whitehouse Station, NJ: Merck & Co., Inc.; June 2021. Available at: www.janumet.com. Accessed September 16, 2021.
4. Janumet XR Prescribing Information. Whitehouse Station, NJ: Merck & Co., Inc.; June 2021. Available at: www.janumetxr.com. Accessed September 16, 2021.
5. Januvia Prescribing Information. Whitehouse Station, NJ: Merck & Co., Inc.; December 2020. Available at: www.januvia.com. Accessed September 16, 2021..
6. Jentadueto Prescribing Information Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; March 2020. Available at: www.jentadueto.com. Accessed September 16, 2021.
7. Jentadueto XR Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; March 2020. Available at: www.jentaduetoxr.com. Accessed September 16, 2021.
8. Kombiglyze XR Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2019. Available at: www.kombiglyzexr.com. Accessed September 16, 2021.
9. Onglyza Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2019. Available at: www.onglyza.com. September 16, 2021.
10. Tradjenta Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; March 2020. Available at: www.tradjenta.com. Accessed September 16, 2021.

11. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997; 102: 491-497.
12. Garber AJ, Abrahamson MJ, Barzilay, JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2020 executive summary. Endocr Pract. 2020; 26(1): 107-139.
13. Qtern Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2020. Available at: www.qtern.com. Accessed September 16, 2021.
14. Steglujan Prescribing Information. Whitehouse Station, NJ: Merck & Co., Inc.; February 2021. Available at www.steglujan.com. Accessed September 16,2021.
15. Trijardy XR Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., June 2021. Available at: https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Trijardy%20XR/Trijardy%20XR.pdf?DMW_FORMAT=pdf. September 16, 2021.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created: adapted from previously corporate approved policy CP.PST.18	09.11.18	11.18
Added AHCCCS non-preferred drugs; added metformin minimum daily doses; modified minimum A1c related for concurrent use of metformin from 9% to 8.5% based on 2019 ADA guidelines; Added requirement for a non-preferred DPP-4 inhibitor/SGLT-2 inhibitor combination therapy: failure of Glyxambi (empagliflozin/linagliptin); Added requirement for documentation of continued metformin therapy (unless contraindicated);	03.22.19	04.19
Added criterion for history of failure of preferred DPP-4 inhibitors for Continued Therapy; Added dosing regimen to Appendix B: Januvia, Janumet, Janumet XR, Jentadueto, Glyxambi, Kombiglyze XR, Onglyza, and Tradjenta.	10.07.19	10.19
1Q 2020 annual review: no significant changes; references reviewed and updated.	10.29.19	02.20
2Q 2020 added information and new drug reference for Trijardy™ XR.	04.2020	04.2020
1Q 2021 annual review: references reviewed and updated.	01.11.21	02.21
AHCCCS preferred Hypoglycemics, Incretin Mimetics update effective 4/1/21: Trijardy XR moved from non-preferred to preferred; Changed calling out therapeutic class to calling out each drug name; Non-preferred DPP-4 inhibitors/metformin	03.18.21	04.21

Reviews, Revisions, and Approvals	Date	P&T Approval Date
combination therapy such as Jentadueto XR and Kazano requests require failure of Janumet/Janumet XR, Jentadueto, and Kombiglyze XR, unless contraindicated or clinically significant adverse effects are experienced; Oseni requests require failure of pioglitazone plus each of the following: [Januvia, Onglyza, and Tradjenta], unless contraindicated or clinically significant adverse effects are experienced; Nesina requests require failure of preferred DPP-4 inhibitors such as Januvia, Onglyza, and Tradjenta, unless contraindicated or clinically significant adverse effects are experienced; Non-preferred DPP-4 inhibitors/SGLT2 inhibitors combination therapy such as Qtern, Qternmet XR, and Steglujan requests require failure of Glyxambi or Trijardy XR, unless contraindicated or clinically significant adverse effects are experienced.		
Added Care1st logo. Added verbiage to specify that criteria also applies to Care1st.	5.10.21	04.21
AHCCCS preferred Hypoglycemics, Incretin Mimetics update effective 10/1/21: Kazano, Nesina, Oseni moved from non-preferred to preferred; Clarified that combination DPP-4 inhibitor and SGLT2 inhibitor requests are to refer to AZ.CP.PMN.14 SGLT2 inhibitor.	09.30.21	10.21
1Q 2022 annual review: no significant changes; removed Qternmet XR as it is no longer on market references reviewed and updated.	01.25.22	02.22

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. "Health Plan" means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

CLINICAL POLICY
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.